Document is current
Any future updates will be listed below
-
Authors
Randolph, Haley E. https://orcid.org/0000-0003-2044-1180
Aguirre-Gamboa, Raúl
Brunet-Ratnasingham, Elsa
Nakanishi, Tomoko https://orcid.org/0000-0001-9510-5646
Mu, Zepeng https://orcid.org/0000-0002-7717-3247
Locher, Veronica
Ketter, Ellen
Brandolino, Cary
Larochelle, Catherine https://orcid.org/0000-0002-8724-4782
Prat, Alexandre https://orcid.org/0000-0001-6188-0580
Arbour, Nathalie https://orcid.org/0000-0002-3718-1584
Dumaine, Anne
Finzi, Andrés https://orcid.org/0000-0002-4992-5288
Durand, Madeleine
Richards, J. Brent https://orcid.org/0000-0002-3746-9086
Kaufmann, Daniel E.
Barreiro, Luis B. https://orcid.org/0000-0001-9456-367X
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (VR2-173203)
Gouvernement du Canada | Canadian Institutes of Health Research (178344)
Gouvernement du Canada | Canadian Institutes of Health Research (365825)
Gouvernement du Canada | Canadian Institutes of Health Research (409511)
Gouvernement du Canada | Canadian Institutes of Health Research (100558)
Gouvernement du Canada | Canadian Institutes of Health Research (169303)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (F31-HL156419)
- License Information
-
More Information
Article History
Received: 21 June 2025
Accepted: 14 April 2026
First Online: 28 April 2026
Competing interests
: J.B.R.’s institution has received investigator-initiated grant funding from Roche, Eli Lilly, GlaxoSmithKline, and Biogen for projects unrelated to this research. J.B.R. is the CEO of, and holds shares in, 5 Prime Sciences, which provides research services for biotech, pharma, and venture capital companies to enable genetics-based drug development. The remaining authors declare no competing interests
